TRIMTECH Therapeutics
Summary Updated Jun 23, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
TRIMTECH Therapeutics is a Cambridge, England biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases 1. The company’s TRIMTAC and TRIMGLUE degraders are designed to selectively degrade toxic protein aggregates and oligomers while leaving the functional monomeric forms of these proteins intact 1. CEO Dr. Nicki Thompson leads the company 1. Following the June 2026 financing, representatives from JJDC and BGF will join the TRIMTECH Therapeutics board as non-executive directors 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-23 | Seed extension | $14M | JJDC (Johnson & Johnson Innovation), BGF | Cambridge Innovation Capital, DDF, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures 12 |
| 2025-03 | Seed | $31M (£25M) | Cambridge Innovation Capital, M Ventures | DDF, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures 3 |
What Investors Say
No independently sourced investor quotes found at this time.
What Founders Say
“This additional funding allows us to forge ahead with developing our portfolio of CNS penetrant degraders based on our unique platforms.” — Dr. Nicki Thompson, CEO 1
Sources
-
BioSpace, “TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio,” June 23, 2026. https://www.biospace.com/press-releases/trimtech-therapeutics-brings-total-seed-round-to-47m-with-additional-investment-of-14m-to-further-develop-trimtac-and-trimglue-targeted-protein-degradation-portfolio↩↩↩↩↩↩
-
News-Medical, “TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M,” June 23, 2026. https://www.news-medical.net/news/20260623/TRIMTECH-Therapeutics-brings-total-seed-round-to-2447-M-with-additional-investment-of-2414-M-to-further-develop-TRIMTAC-and-TRIMGLUE-targeted-protein-degradation-portfolio.aspx↩
-
Cambridge Innovation Capital, “Cambridge Innovation Capital co-leads $31M seed financing for TRIMTECH Therapeutics,” accessed June 2026. https://www.cic.vc/cambridge-innovation-capital-co-leads-31m-seed-financing-for-trimtech-therapeutics-to-advance-neurodegenerative-disease-treatments/↩